Research opportunities for pathogen reduction/inactivation of blood components: Summary of an NHLBI workshop

Transfusion

Volumn 49, Issue 6, 2009, Pages 1262-1268

  Blajchman, Morris A ^a   Klein, Harvey G ^b   Glynn, Simone A ^b   Ness, Paul M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b McMaster University ^*

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9; THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; ANAPHYLAXIS; BLOOD COMPONENT; BLOOD TRANSFUSION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FEVER; GAMMA IRRADIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MEDICAL CARE; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; PATHOGENESIS; RISK FACTOR; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; VASCULARIZATION;

BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; COST-BENEFIT ANALYSIS; DISINFECTION; ERYTHROCYTES; HUMANS; PLASMA;

EID: 66549119064     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02210.x     Document Type: Conference Paper

References (33)

1. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007 21 : 101 17.
2. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfold DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H, SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006 20 : 273 82.
3. Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008 22 : 97 102.
4. Klein HG, Anderson D. Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007 47 : 2338 47.
5. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009 Feb 2. [Epub ahead of print WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008 95 : 13 9.
6. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007 47 : 1381 9.
7. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007 131 : 719 33.
8. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008 22 : 1 34. (Pubitemid 350193270)
9. Washington, DC : Department of Health and Human Services. Available from: http://www.hhs.gov/ophs/bloodsafety/recommendation/resjan08.pdf (accessed Jan 26, 2009).
10. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 45 : 580 90.
11. Lin L, Dikeman R, Molini B, Likehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004 44 : 1496 504.
12. Castro E, Gironés N, Bueno JL, Carrión J, Lin L, Fresno M. The efficacy of photochemical treatment with amotosalen HCI and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007 47 : 434 41.
13. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopes-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th., Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004 104 : 1534 41.
14. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JA, Corash L, Conlan MG SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCI and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005 45 : 1864 75.
15. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Hervé P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002 42 : 1356 64.
16. Robillard P, Nawej KI, Jochem K. The Quebec hemovigilance system: description and results from the first two years. Transfus Apher Sci 2004 31 : 111 22.
17. AuBuchon JP, Whitaker BI. America finds hemovigilance! Transfusion 2007 47 : 1937 42.
18. Ruane PH, Edrich R. Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
19. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Medez J, Reddy H, Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006 90 : 85 91. (Pubitemid 43381495)
20. Fast LD, Semple JW, DiLeone G, Kin N, Freedman J, Chapman J, Purmal A. Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs. Transfusion 2004 44 : 282 5.
21. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/-double knockout mice. Transfusion 2006 46 : 1553 60.
22. Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
23. Rios JA, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, Wages D, Cook D, Corash L. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006 46 : 1778 86.
24. Zavizion B, Pereira M, de Melo JM, Serebryanik D, Mather TN, Chapman J, Miller NJ, Alford B, Bzik DJ, Purmal A. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004 44 : 731 8.
25. Goodrich RP, Murthy KK, Doane SK, Fitzpatrick CN, Morrow LS, Arndt PA, Reddy HL, Buytaert-Hoefen KA, Garratty G. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 2009 49 : 64 74.
26. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009 23 : 124 33.
27. Garwood M, Cardigan RA, Drummond O, Hornsey VS, Tuner CP, Young D, Williamson LM, Prowse CV. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003 43 : 1238 47.
28. Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008 38 : 271 80.
29. Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP. Photochemical treatment of plasma with amotosalen and UVA light; process validation in three European blood centers. Transfusion 2008 48 : 697 705.
30. Goodrich R, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17. (Pubitemid 44354317)
31. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 48 : 1061 71.
32. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009 23 : 1 12.
33. Kleinman S, Dumont LJ, Tomasulo P, Bianco C, Katz L, Benjamin RJ, Gajic O, Brecher M. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion 2009 Jan 5 Epub ahead of print ].